Chenguang Biotech Group (300138) — Strategic Asset Allocation Index
Chenguang Biotech Group (300138) has a Strategic Asset Allocation Index of 45.6% as of June 2023. Strategic assets (PP&E of CN¥1.58 Billion plus long-term investments of CN¥-) total CN¥1.58 Billion, measured against net assets of CN¥3.46 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Chenguang Biotech Group Strategic Asset Allocation Index (2007–2022)
This chart shows how Chenguang Biotech Group's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of June 2023, the index stands at 45.6%, representing strategic assets of CN¥1.58 Billion against net assets of CN¥3.46 Billion CNY. Explore Chenguang Biotech Group (300138) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Chenguang Biotech Group (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Chenguang Biotech Group from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Chenguang Biotech Group.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 47.9% | CN¥1.54 Billion | CN¥1.54 Billion | CN¥- | CN¥3.21 Billion | ▼ -5.4 pp |
| 2021 | 53.3% | CN¥1.48 Billion | CN¥1.48 Billion | CN¥- | CN¥2.78 Billion | ▼ -7.1 pp |
| 2020 | 60.4% | CN¥1.24 Billion | CN¥1.24 Billion | CN¥- | CN¥2.06 Billion | ▲ +7.3 pp |
| 2019 | 53.1% | CN¥924.23 Million | CN¥924.23 Million | CN¥- | CN¥1.74 Billion | ▲ +3.6 pp |
| 2018 | 49.4% | CN¥860.38 Million | CN¥778.00 Million | CN¥82.37 Million | CN¥1.74 Billion | ▲ +7.1 pp |
| 2017 | 42.4% | CN¥688.08 Million | CN¥656.58 Million | CN¥31.50 Million | CN¥1.62 Billion | ▲ +4.9 pp |
| 2016 | 37.4% | CN¥570.95 Million | CN¥564.45 Million | CN¥6.50 Million | CN¥1.52 Billion | ▲ +2.3 pp |
| 2015 | 35.2% | CN¥502.10 Million | CN¥502.10 Million | CN¥- | CN¥1.43 Billion | ▼ -12.9 pp |
| 2014 | 48.1% | CN¥484.61 Million | CN¥484.61 Million | CN¥- | CN¥1.01 Billion | ▼ -11.9 pp |
| 2013 | 59.9% | CN¥593.37 Million | CN¥593.37 Million | CN¥- | CN¥990.39 Million | ▲ +4.9 pp |
| 2012 | 55.0% | CN¥548.63 Million | CN¥548.63 Million | CN¥- | CN¥997.86 Million | ▲ +13.8 pp |
| 2011 | 41.1% | CN¥398.61 Million | CN¥398.61 Million | CN¥- | CN¥968.71 Million | ▲ +17.4 pp |
| 2010 | 23.8% | CN¥221.98 Million | CN¥221.98 Million | CN¥- | CN¥933.05 Million | ▼ -29.9 pp |
| 2009 | 53.7% | CN¥113.05 Million | CN¥113.05 Million | CN¥- | CN¥210.67 Million | ▲ +0.8 pp |
| 2008 | 52.9% | CN¥78.26 Million | CN¥78.26 Million | CN¥- | CN¥147.93 Million | ▲ +9.3 pp |
| 2007 | 43.6% | CN¥44.33 Million | CN¥44.33 Million | CN¥- | CN¥101.70 Million | — |